2 studies found for:    NCT00390221
Show Display Options
Download search resultsDownload the search results for:
NCT00390221 (2 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Subjects With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis.
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Daclizumab High Yield Process 150 mg;   Biological: Daclizumab High Yield Process 300 mg
2 Completed Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BIIB019 (Daclizumab High Yield Process);   Drug: Placebo

Indicates status has not been verified in more than two years